Earnings Reports and Performance (AI Boom Validation)
Samsung Electronics Q3: Sales of 195 trillion won (YoY +127%); operating profit of 107.4 trillion won (YoY +783%, roughly a ninefold increase). Fourth consecutive quarter of record highs, driven by AI memory demand; however, there are signs that memory price hikes are starting to slow.
TSMC Q3: Revenue up 50% year over year, also a record, validating the continued momentum in building AI infrastructure.
Micron Technology $MUB FY26 Q4: Adjusted revenue of $54.23 billion; expects FY27 Q1 revenue of $60.0–63.0 billion. The CEO said that HBM demand growth will continue to outpace traditional DRAM through 2028.
Institutional Ratings and In-Depth Analysis
Market Outlook (Bank of America): The yield on the 10-year U.S. Treasury has already exceeded 5%, creating “real competition” with U.S. equities; elevated interest rates are suppressing valuations.
Analyst Rating Changes (集中调整 on 10/8):
Apple: Up to Buy (new iPhone + expansion of services)
Amazon: Down to Sell (intensifying e-commerce competition; thinner profit margins)
Alphabet / Netflix / Tesla: Maintain Buy
Microsoft / Meta: Maintain Hold (regulatory and capital expenditure considerations)
Coinbase split: Barclays target price $149 (bearish), Goldman Sachs $244 (bullish), reflecting sharp divergence in how crypto stocks are priced.
Market Sentiment: GLOBALT view—After the stock market rose more than expected in Q3, some investors chose to take profits; oil prices fell and Treasury auction demand remained strong, leading to a narrowing of losses late in the day.
Biotechnology / FDA / Clinical
FDA approves Eli Lilly $LLYB Jaypirca (pirtobrutinib) for first-line use in CLL/SLL: In the BRUIN CLL-313 study, the PFS risk ratio is 0.20 (vs. bendamustine + rituximab), reducing progression/death risk by 80%.
Novartis makes a $575 million upfront payment to acquire Abogen’s mRNA T-cell engager; CSL bets $355 million on Alentis.
Genmab Rina-S (folate receptor ADC): ORR 45.9% in platinum-resistant ovarian cancer (109 patients; 5 complete responses), with no ocular or neurotoxicity signals; RAINFOL-02 Phase III enrollment is underway.
CStone Pharmaceuticals CS2009 (PD-1/VEGF/CTLA-4 triple agonist) approved by the FDA for Phase II clinical trials for late-stage solid tumors.
Novo Nordisk denecimig (BLA) review delayed: due to factory rectification; not a clinical/nonclinical data issue. Target listing in the U.S. in H1 2027.
Strait of Hormuz situation: Iran’s Revolutionary Guard says it has sealed the strait as an “illegal waterway”; U.S. Central Command denies the closure, saying traffic remains flowing, about 20 million barrels of crude oil $CL through it
Samsung Electronics Q3: Sales of 195 trillion won (YoY +127%); operating profit of 107.4 trillion won (YoY +783%, roughly a ninefold increase). Fourth consecutive quarter of record highs, driven by AI memory demand; however, there are signs that memory price hikes are starting to slow.
TSMC Q3: Revenue up 50% year over year, also a record, validating the continued momentum in building AI infrastructure.
Micron Technology $MUB FY26 Q4: Adjusted revenue of $54.23 billion; expects FY27 Q1 revenue of $60.0–63.0 billion. The CEO said that HBM demand growth will continue to outpace traditional DRAM through 2028.
Institutional Ratings and In-Depth Analysis
Market Outlook (Bank of America): The yield on the 10-year U.S. Treasury has already exceeded 5%, creating “real competition” with U.S. equities; elevated interest rates are suppressing valuations.
Analyst Rating Changes (集中调整 on 10/8):
Apple: Up to Buy (new iPhone + expansion of services)
Amazon: Down to Sell (intensifying e-commerce competition; thinner profit margins)
Alphabet / Netflix / Tesla: Maintain Buy
Microsoft / Meta: Maintain Hold (regulatory and capital expenditure considerations)
Coinbase split: Barclays target price $149 (bearish), Goldman Sachs $244 (bullish), reflecting sharp divergence in how crypto stocks are priced.
Market Sentiment: GLOBALT view—After the stock market rose more than expected in Q3, some investors chose to take profits; oil prices fell and Treasury auction demand remained strong, leading to a narrowing of losses late in the day.
Biotechnology / FDA / Clinical
FDA approves Eli Lilly $LLYB Jaypirca (pirtobrutinib) for first-line use in CLL/SLL: In the BRUIN CLL-313 study, the PFS risk ratio is 0.20 (vs. bendamustine + rituximab), reducing progression/death risk by 80%.
Novartis makes a $575 million upfront payment to acquire Abogen’s mRNA T-cell engager; CSL bets $355 million on Alentis.
Genmab Rina-S (folate receptor ADC): ORR 45.9% in platinum-resistant ovarian cancer (109 patients; 5 complete responses), with no ocular or neurotoxicity signals; RAINFOL-02 Phase III enrollment is underway.
CStone Pharmaceuticals CS2009 (PD-1/VEGF/CTLA-4 triple agonist) approved by the FDA for Phase II clinical trials for late-stage solid tumors.
Novo Nordisk denecimig (BLA) review delayed: due to factory rectification; not a clinical/nonclinical data issue. Target listing in the U.S. in H1 2027.
Strait of Hormuz situation: Iran’s Revolutionary Guard says it has sealed the strait as an “illegal waterway”; U.S. Central Command denies the closure, saying traffic remains flowing, about 20 million barrels of crude oil $CL through it